Actively Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Led by Beijing Chao Yang Hospital · Updated on 2026-04-30
2400
Participants Needed
5
Research Sites
47 weeks
Total Duration
On this page
Sponsors
B
Beijing Chao Yang Hospital
Lead Sponsor
C
Capital Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying lung cancer patients receiving immune checkpoint inhibitors (ICIs) to understand how often venous thromboembolism (VTE) and arterial thromboembolism (ATE) occur, what risk factors and biomarkers are involved, and how these events affect patient outcomes. The study aims to identify specific biomarkers linked to thrombotic events and develop a risk prediction model to support personalized prevention and treatment in clinical care. This observational study divides participants into groups based on whether they experience ICI-associated VTE or ATE. Researchers compare patient characteristics and biomarkers between those with and without these thrombotic events to find new markers and risk factors. Data collection begins at the first dose of ICIs and continues until death, the start of other cancer treatments, or three months after the last ICI dose, with follow-up lasting up to 96 months. During the study, participants are monitored for thrombotic events and their impact on progression-free survival, overall survival, and response to treatment. Key outcomes are assessed through clinical data and biomarkers collected over time. The research team tracks these outcomes from treatment start through a long-term follow-up period, aiming to improve understanding of thrombosis risks in lung cancer patients receiving ICIs.
CONDITIONS
Brief Title
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6528 years
- Histopathologically confirmed lung cancer diagnosis at enrollment
- Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
- Signed informed consent form
You will not qualify if you...
- Presence of two or more primary cancers
- Missing data for key variables
- Inability to comply with follow-up requirements
- Presence of VTE/ATE at the time of ICI initiation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 96 months
Participants are monitored from the first dose of immune checkpoint inhibitors until death, start of other systemic anticancer therapy, or 3 months after the last dose, for up to 96 months.
Trial Site Locations
Total: 5 locations
1
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Actively Recruiting
2
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot, Inner Mongolia, China
Actively Recruiting
3
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
Actively Recruiting
4
Beijing Luhe Hospital, Capital Medical University
Beijing, China
Actively Recruiting
5
China-japan Friendship Hospital
Beijing, China
Actively Recruiting
Research Team
Y
Yuhui Zhang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here